Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Thymogen

Glu-Trp, EW dipeptide, Oglufanide, L-Glutamyl-L-tryptophan

Quick Stats
Studies 94
Trials 51
Unknown PHASE2, PHASE3 INTERVENTIONAL NCT00386022

The Effects of Aging and Estrogen on the Pituitary

View on ClinicalTrials.gov Updated Dec 15, 2025

Brief Summary

The purpose of this study is to study the effects of aging and estrogen on the brain. Specifically, this study will examine how the hypothalamus signals the pituitary gland to secrete reproductive hormones and how that changes with aging.

Detailed Description

Although it is clear that loss of ovarian function plays a major role in the menopause in women, there is evidence from animal studies that primary age-related hypothalamic and pituitary changes may also contribute to reproductive aging. Complete cessation of ovarian function results in the loss of negative feedback of ovarian steroids and inhibin on the hypothalamic and pituitary components of the reproductive axis. An increase in serum levels of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) occurs in postmenopausal women with removal of negative ovarian feedback. However, levels of LH and FSH after menopause decline steadily as a function of age in most though not all studies. The current study is designed to determine: 1) whether negative feedback on LH and FSH occurs at the pituitary; and 2) whether there is an effect of aging on estrogen negative feedback at the pituitary. Younger and older postmenopausal women underwent a baseline study and a second identical study after a month of low dose estrogen replacement. The study protocol consisted of the following: 1) administration of a GnRH antagonist (Nal-Glu at 150 mg/kg that blocks endogenous GnRH so that the dose and interval of pituitary exposure to GnRH are precisely controlled; 2) beginning 8 hours following GnRH antagonist administration (at a time when LH had reached its nadir following GnRH receptor blockade), administration of 4 graded doses of GnRH (25, 75, 250 and 750 ng/kg every 2 hours with 2 hours of blood draws following each dose). Blood was sampled every 30 min for 4 hours before antagonist administration, every 30 min for the following 7 hours and then every 10 min until the completion of the study.

Interventions

Name: GnRH
Type: DRUG
Description: GnRH doses of 25, 75, 250 and 750 ng/kg will be given IV every 4 hr at baseline and after transdermal estradiol
Name: NAL-GLU GnRH antagonist
Type: DRUG
Description: A single subcutaneous injection of the NAL-GLU GnRH antagonist at a dose of 150 mcg/kg before and after transdermal estradiol
Name: Estrogen patch
Type: DRUG
Description: transdermal estrogen patches 0.05mg/day, changing the patch every 86 hr in second part of sequential study

Primary Outcomes

Measure: Pituitary Response to GnRH
TimeFrame: Peak hormone level within 2 hours post GnRH doses
Description: Baseline LH and FSH responses to each of 4 GnRH doses - peak to nadir amplitude expressed as percent (%) change from nadir
Measure: Effect of Estrogen on Pituitary Response to GnRH
TimeFrame: Peak hormone level within 2 hours post GnRH doses
Description: LH and FSH responses to each of 4 GnRH doses, expressed as change in amplitude \[amp\] from peak to nadir between plus estrogen and baseline conditions

Trial Information

NCT ID

NCT00386022

Status

Unknown

Study Type

INTERVENTIONAL

Phases

PHASE2, PHASE3

Sponsor

Massachusetts General Hospital

Last Updated

December 15, 2025